GeoVax CEO David Dodd to Participate in Virtual Webinar Hosted by Outsourced Pharma
October 28 2020 - 9:00AM
via NewMediaWire --
GeoVax Labs,
Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the
“Company”), a biotechnology company developing human
immunotherapies and vaccines against infectious diseases and
cancer, today announces that CEO and Chairman David Dodd will
participate in an upcoming virtual webinar titled, “What COVID-19
Vaccines Teach Us About All Tech Transfers.” Sponsored by
Outsourced Pharma (www.outsourcedpharma.com), the event will be
held on Wednesday, November 4, 2020 at 2:00pm ET. Discussion
topics include the lessons learned and best practices from the
COVID-19 vaccine efforts that can be applied to technology
transfers.
Mr. Dodd will be joined by three other industry veterans along
with Louis Garguilo, panel moderator and Chief Editor at Outsourced
Pharma.
Investors wishing to watch the webinar can
register for the event here:
https://event.on24.com/wcc/r/2733609/8D3DC8ADE39C05C9EAF19545B1A8A22F
The webinar will build on the discussion first
highlighted in the online article found here:
https://www.outsourcedpharma.com/doc/years-for-vaccine-tech-transfers-covid-won-t-wait-0001
About COVID-19
Coronaviruses are common in many species of
animals, including bats and birds. These viruses can evolve to
cross the animal species and infect humans and quickly spread from
person to person resulting in lethal but rare respiratory
infections. Recent epidemics with SARS and MERS coronaviruses
resulted in 774 and 858 deaths, respectively. Since 2015 there have
not been any cases of SARS and MERS reported, but in January 2020,
World Health Organization (WHO) identified a novel coronavirus,
recently named SARS-CoV-2, in the city of Wuhan, China. On January
31, 2020 the WHO declared the novel coronavirus to be a global
health emergency, and on March 11, 2020 the WHO declared a global
pandemic. Worldwide, more than 41 million people have been infected
(over 8.3 million in the U.S.), with more than 1.1 million deaths
(over 200,000 in the U.S). The situation is fluid, with the
infection and death statistics changing significantly on a regular
basis.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage
biotechnology company developing human vaccines against infectious
diseases and cancer using a novel patented Modified Vaccinia
Ankara-Virus Like Particle (MVA-VLP) based vaccine platform.
On this platform, MVA, a large virus capable of carrying
several vaccine antigens, expresses proteins that assemble into VLP
immunogens within (in vivo) the person receiving the vaccine.
The production of VLPs in the person being vaccinated mimics
virus production in a natural infection, stimulating both the
humoral and cellular arms of the immune system to recognize,
prevent, and control the target infection. The MVA-VLP
derived vaccines elicit durable immune responses in the host
similar to a live-attenuated virus, while providing the safety
characteristics of a replication-defective vector.
GeoVax’s current development programs are focused
on preventive vaccines against COVID-19, HIV, Zika Virus,
hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and
malaria, as well as therapeutic vaccines against multiple cancers.
The Company has designed a preventive HIV vaccine candidate to
fight against the subtype of HIV prevalent in the commercial
markets of the Americas, Western Europe, Japan, and Australia.
Human clinical trials for this program are managed by the HIV
Vaccine Trials Network (HVTN) with the support of the National
Institutes of Health (NIH). GeoVax’s HIV vaccine candidate is
also part of two separate collaborative efforts to apply its
innovative gene therapy approach toward a functional cure for
HIV.
Cautionary Note
Regarding Forward-Looking Statements
This release contains forward-looking statements
regarding the timing and success of the proposed offering and the
timing and financial impact of GeoVax’s ability to implement its
business plan, expected revenues and future success. The words
“believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,”
“should,” “plan,” “could,” “target,” “potential,” “is likely,”
“will,” “expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs. Actual
results may differ materially from those included in these
statements due to a variety of factors, including whether: GeoVax
can develop and manufacture its vaccines with the desired
characteristics in a timely manner, GeoVax’s vaccines will be safe
for human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s vaccines will receive regulatory
approvals necessary to be licensed and marketed, GeoVax raises
required capital to complete vaccine development, there is
development of competitive products that may be more effective or
easier to use than GeoVax’s products, GeoVax will be able to enter
into favorable manufacturing and distribution agreements, the
impact of the COVID-19 pandemic continues, and other factors, over
which GeoVax has no control.
Further information on our risk factors is
contained in our registration statement on Form S-1 (File No.
333-239958) that we have filed with the SEC and the final
prospectus. Any forward-looking statement made by us herein
speaks only as of the date on which it is made. Factors or events
that could cause our actual results to differ may emerge from time
to time, and it is not possible for us to predict all of them. We
undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future
developments or otherwise, except as may be required by law.
GeoVax Labs, Inc. 678-384-7220 investor@geovax.com
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Apr 2023 to Apr 2024